Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.

Rafei H, Kantarjian HM, Jabbour EJ.

Br J Haematol. 2019 Sep 30. doi: 10.1111/bjh.16207. [Epub ahead of print] Review.

PMID:
31566728
2.

Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.

Jabbour EJ, Gökbuget N, Kantarjian HM, Thomas X, Larson RA, Yoon SS, Ghobadi A, Topp MS, Tran Q, Franklin JL, Forman SJ, Stein AS.

Cancer. 2019 Aug 21. doi: 10.1002/cncr.32335. [Epub ahead of print]

PMID:
31433496
3.

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM.

Lancet Haematol. 2019 Sep;6(9):e480-e488. doi: 10.1016/S2352-3026(19)30114-0. Epub 2019 Aug 7.

PMID:
31400961
4.

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.

Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F.

Cancer. 2019 Nov 1;125(21):3755-3766. doi: 10.1002/cncr.32387. Epub 2019 Jul 16.

PMID:
31310323
5.

SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.

Paul S, Rausch CR, Welch MA, Kantarjian HM, Jabbour EJ.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):471-479. doi: 10.1016/j.clml.2019.06.011. Epub 2019 Jul 3. Review.

PMID:
31307896
6.

Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?

Sasaki K, Kantarjian HM, Jabbour EJ.

Cancer. 2019 Nov 1;125(21):3891-3892. doi: 10.1002/cncr.32385. Epub 2019 Jul 10. No abstract available.

PMID:
31291004
7.

Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.

Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M.

Leuk Lymphoma. 2019 Jun 27:1-4. doi: 10.1080/10428194.2019.1633635. [Epub ahead of print] No abstract available.

PMID:
31246142
8.

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.

Guerra VA, Jabbour EJ, Ravandi F, Kantarjian H, Short NJ.

Ther Adv Hematol. 2019 May 19;10:2040620719849496. doi: 10.1177/2040620719849496. eCollection 2019. Review.

9.

Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.

Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour EJ, Kantarjian HM, Medeiros LJ, Khoury JD.

Br J Haematol. 2019 Aug;186(4):538-548. doi: 10.1111/bjh.15960. Epub 2019 May 22.

PMID:
31115909
10.

Recent advances in the treatment of acute lymphoblastic leukemia.

Rafei H, Kantarjian HM, Jabbour EJ.

Leuk Lymphoma. 2019 May 16:1-16. doi: 10.1080/10428194.2019.1605071. [Epub ahead of print]

PMID:
31092071
11.

Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US.

Jabbour EJ, Mendiola MF, Lingohr-Smith M, Lin J, Makenbaeva D.

J Med Econ. 2019 Nov;22(11):1113-1118. doi: 10.1080/13696998.2019.1618316. Epub 2019 May 31.

PMID:
31074658
12.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM.

Cancer. 2019 Aug 1;125(15):2579-2586. doi: 10.1002/cncr.32139. Epub 2019 Apr 15.

PMID:
30985931
13.

Treatment of relapsed/refractory acute lymphoblastic leukemia.

Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ.

Clin Adv Hematol Oncol. 2019 Mar;17(3):166-175. Review.

PMID:
30969955
14.

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE.

Int J Hematol. 2019 May;109(5):545-552. doi: 10.1007/s12185-019-02620-2. Epub 2019 Mar 4.

PMID:
30830579
15.

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.

Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1347-1354. doi: 10.1016/j.bbmt.2019.02.022. Epub 2019 Mar 1.

PMID:
30826465
16.

Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.

Corbacioglu S, Jabbour EJ, Mohty M.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1271-1280. doi: 10.1016/j.bbmt.2019.02.018. Epub 2019 Feb 22. Review.

17.

Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.

Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK.

Cancer. 2019 May 15;125(10):1665-1673. doi: 10.1002/cncr.31923. Epub 2019 Jan 22.

PMID:
30668890
18.

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.

Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F.

Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):142-148.e1. doi: 10.1016/j.clml.2018.12.009. Epub 2018 Dec 20.

PMID:
30635233
19.

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.

Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S.

Leuk Lymphoma. 2019 Jul;60(7):1767-1774. doi: 10.1080/10428194.2018.1543876. Epub 2019 Jan 11.

PMID:
30632841
20.

Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report.

Burgos S, Montalban-Bravo G, Fuente L, Jabbour EJ, Kanagal-Shamanna R, Soltysiak KA, Garcia-Manero G, Mela-Osorio MJ.

Medicine (Baltimore). 2019 Jan;98(1):e14011. doi: 10.1097/MD.0000000000014011.

21.

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.

Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F.

Cancer. 2019 Apr 1;125(7):1091-1100. doi: 10.1002/cncr.31885. Epub 2018 Dec 6.

PMID:
30521114
22.

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.

Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG.

Cancer. 2019 May 1;125(9):1470-1481. doi: 10.1002/cncr.31896. Epub 2018 Nov 30.

23.

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.

Angelova E, Audette C, Kovtun Y, Daver N, Wang SA, Pierce S, Konoplev SN, Khogeer H, Jorgensen JL, Konopleva M, Zweidler-McKay PA, Medeiros LJ, Kantarjian HM, Jabbour EJ, Khoury JD.

Haematologica. 2019 Apr;104(4):749-755. doi: 10.3324/haematol.2018.205252. Epub 2018 Oct 25.

24.

Correction: Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6.

Li J, Xu J, Abruzzo LV, Tang G, Li S, You MJ, Lu G, Jabbour EJ, Deng Q, Bueso-Ramos CE, Medeiros LJ, Yin CC.

Oncotarget. 2018 Sep 28;9(76):34449. doi: 10.18632/oncotarget.26205. eCollection 2018 Sep 28.

25.

Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value.

Hidalgo-Lόpez JE, Kanagal-Shamanna R, Quesada AE, Gong Z, Wang W, Hu S, Medeiros LJ, Bassett RL Jr, d'Orcy E, Yin CC, Cortes J, Jabbour EJ, Kantarjian HM, Bueso-Ramos CE.

Cancer. 2018 Oct 1;124(19):3849-3855. doi: 10.1002/cncr.31663. Epub 2018 Oct 15.

26.

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N.

Blood. 2018 Oct 18;132(16):1664-1674. doi: 10.1182/blood-2018-04-846626. Epub 2018 Sep 5.

27.

Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States.

Jabbour EJ, Siegartel LR, Lin J, Lingohr-Smith M, Menges B, Makenbaeva D.

Leuk Lymphoma. 2019 Mar;60(3):668-674. doi: 10.1080/10428194.2018.1492124. Epub 2018 Aug 20.

PMID:
30124372
28.

P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival.

Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, Daver N, Tashakori M, Kadia T, Routbort M, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour EJ, Kornblau SM, Medeiros LJ, Kantarjian H, Khoury JD.

Am J Hematol. 2018 Nov;93(11):1376-1383. doi: 10.1002/ajh.25255. Epub 2018 Sep 23.

PMID:
30117185
29.

Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model.

Jabbour EJ, Siegartel LR, Lin J, Lingohr-Smith M, Menges B, Makenbaeva D.

J Med Econ. 2018 Oct;21(10):1036-1040. doi: 10.1080/13696998.2018.1508023. Epub 2018 Aug 15.

PMID:
30071761
30.

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.

Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, Jabbour EJ, Pemmaraju N, Kanagal-Shamanna R, Gur HD, Hu S, Zuo Z, Medeiros LJ, Kantarjian HM, Khoury JD.

Blood Adv. 2018 Aug 14;2(15):1807-1816. doi: 10.1182/bloodadvances.2018019224.

31.

Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases.

Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, Kadia TM, Jabbour EJ, Lasho T, Hanson CA, Ketterling RP, Kantarjian HM, Tefferi A, Garcia-Manero G.

Leukemia. 2018 Nov;32(11):2512-2518. doi: 10.1038/s41375-018-0143-8. Epub 2018 Apr 25. No abstract available.

32.

Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6.

Li J, Xu J, Abruzzo LV, Tang G, Li S, You MJ, Lu G, Jabbour EJ, Deng Q, Bueso-Ramos CE, Medeiros LJ, Yin CC.

Oncotarget. 2017 Dec 15;9(13):10987-10994. doi: 10.18632/oncotarget.23743. eCollection 2018 Feb 16. Erratum in: Oncotarget. 2018 Sep 28;9(76):34449.

33.

Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.

Kantarjian HM, Su Y, Jabbour EJ, Bhattacharyya H, Yan E, Cappelleri JC, Marks DI.

Cancer. 2018 May 15;124(10):2151-2160. doi: 10.1002/cncr.31317. Epub 2018 Mar 6.

34.

Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia.

Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M.

Oncotarget. 2018 Jan 17;9(8):8027-8041. doi: 10.18632/oncotarget.24261. eCollection 2018 Jan 30.

35.

Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.

Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL Jr, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF.

Clin Cancer Res. 2018 May 15;24(10):2304-2311. doi: 10.1158/1078-0432.CCR-17-3561. Epub 2018 Feb 23.

36.

Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools.

Kurt H, Jorgensen JL, Amin HM, Patel KP, Wang SA, Lin P, Kanagal-Shamanna R, Loghavi S, Thakral B, Khogeer HA, Jabbour EJ, Li S, Yin CC, Medeiros LJ, Khoury JD.

Eur J Haematol. 2018 May;100(5):444-454. doi: 10.1111/ejh.13038. Epub 2018 Mar 9.

PMID:
29385279
37.

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.

Jabbour EJ, DeAngelo DJ, Stelljes M, Stock W, Liedtke M, Gökbuget N, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM.

Cancer. 2018 Apr 15;124(8):1722-1732. doi: 10.1002/cncr.31249. Epub 2018 Jan 30.

38.

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.

Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T.

Leuk Lymphoma. 2018 Sep;59(9):2238-2241. doi: 10.1080/10428194.2017.1422864. Epub 2018 Jan 17. No abstract available.

PMID:
29338567
39.

First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia.

Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour EJ, Ferrajoli A, Konoplev SN, Kantarjian HM, Bose P.

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00127. Epub 2018 Aug 22. No abstract available.

40.

Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies.

Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour EJ, Milton DR, Bassett RL Jr, Vence LM, Allison JP, Gulbis AM, Sharma P.

Clin Cancer Res. 2018 Mar 1;24(5):1011-1018. doi: 10.1158/1078-0432.CCR-17-2777. Epub 2017 Dec 15.

41.

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.

Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F.

Leukemia. 2018 Jan;32(1):241-244. doi: 10.1038/leu.2017.285. Epub 2017 Sep 18. No abstract available.

PMID:
28919634
42.

Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.

Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G.

Cancer. 2017 Dec 15;123(24):4851-4859. doi: 10.1002/cncr.30949. Epub 2017 Aug 25.

43.

Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.

Paul S, Rausch CR, Kantarjian H, Jabbour EJ.

Future Oncol. 2017 Oct;13(25):2233-2242. doi: 10.2217/fon-2017-0233. Epub 2017 Aug 4. Review.

PMID:
28776425
44.

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.

Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE.

Cancer. 2017 Nov 15;123(22):4391-4402. doi: 10.1002/cncr.30864. Epub 2017 Jul 25.

45.

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.

Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, Ejduk AA, O'Brien SM, Jabbour EJ, Zhang H, Sleight BJ, Vandendries ER, Marks DI.

Lancet Haematol. 2017 Aug;4(8):e387-e398. doi: 10.1016/S2352-3026(17)30103-5. Epub 2017 Jul 4.

PMID:
28687420
46.

Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.

Jabbour EJ, Lin J, Siegartel LR, Lingohr-Smith M, Menges B, Makenbaeva D.

J Med Econ. 2017 Sep;20(9):1007-1012. doi: 10.1080/13696998.2017.1345750. Epub 2017 Jul 6.

PMID:
28681664
47.

Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.

Khouri MR, Jabbour EJ, Gulbis AM, Turturro F, Ledesma C, Korbling M, Samuels BI, Ahmed S, Alousi AM, Ciurea SO, Marin D, Patel KK, Popat UR, Bueso-Ramos CE, Bassett RL Jr, Khouri IF.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1405-1410. doi: 10.1016/j.bbmt.2017.04.027. Epub 2017 May 8.

48.

Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome.

Kanagal-Shamanna R, Hidalgo Lopez JE, Milton DR, Kim HR, Zhao C, Zuo Z, Janania Martinez M, Stingo F, Lee J, Luthra R, Jabbour EJ, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE.

Am J Hematol. 2017 Aug;92(8):E168-E171. doi: 10.1002/ajh.24776. Epub 2017 May 30. No abstract available.

49.

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.

Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM.

Cancer. 2017 Aug 15;123(16):3050-3060. doi: 10.1002/cncr.30704. Epub 2017 Apr 7.

50.

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.

Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G.

Am J Hematol. 2017 Jul;92(7):599-606. doi: 10.1002/ajh.24735. Epub 2017 May 26.

Supplemental Content

Loading ...
Support Center